Daily News Alerts
Canadian Benchmarking Study Focused on Multi-Employer and Target Benefit Pension Plans
Published By: PBI Actuarial Consultants | 29/01/2021
What are other pension plans doing that might also benefit your plan and its members? How do your plan’s contribution and benefit rates compare to others? What has been the effect of the COVID-19 pandemic on MEPP/TBP plans? Could you improve your pension plan’s risk efficiency? Find the answers to these questions and more in the 2021 Apples & Oranges Study.
Recent Research Papers
Strategy Needed For High Cost Drugs
February 25, 2021
Drug plan managers have long struggled to address the management of high cost drugs which, on one hand, vastly improve claimants’ health outcomes and provide better quality of life, but, on the other hand, have an ever-expanding place in group health benefits’ budgets. In ‘Specialty Drug Strategy: How To Look Beyond The (High) Cost With A Five-Pillar Approach,’ Christine Than, a pharmacist and drug solution specialist at Aon, says while the use of specialty drugs, account for only for about one per cent of all drug claims, they represent approximately 35 per cent on average of total drug plan spend. When addressing specialty drug coverage, an employer’s drug cost containment strategy should be coherent with their total rewards strategy, she says.
- Research (PDF): Assessing The Environment Cost Of eCommerce
- Research (PDF): Changing Workplaces Require New Benefit Approaches
- Research (PDF): CAP To The Future: Decumulation In CAP Plans
- Research (PDF): Corporate Wellness Turns To Virtual Progamming
- Research (PDF): Vaccines And The Workplace ‒ Let The Battles Begin
Interested in Advertising on our Website or Magazine? Contact our Sales Team